Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blinded, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ZL-1109 in Chinese Participants With Thyroid Eye Disease (TED)

NCT07211776 is registered in ClinicalTrials.gov with Zai Lab (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT07211776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07211776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blinded, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ZL-1109 in Chinese Participants With Thyroid Eye Disease (TED)
Lead sponsor
Zai Lab (Shanghai) Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 5, 2025
Completion date
January 29, 2028
Enrollment
108 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease (ted)